|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1999-1-4
|
|
pubmed:abstractText |
We investigated the pharmacological characteristics of Z-335 ((+/-)-sodium[2-[4-(chlorophenylsulfonylaminomethyl)indan-5-yl]ace tate monohydrate), a new indan derivative. Z-335 inhibited the specific binding of [3H]SQ-29548 to human platelets and guinea pig platelet membranes. The IC50 values of Z-335 for human platelets and guinea pig platelet membranes were 29.9 +/- 3.1 nM with a slope of 1.09 +/- 0.05 and 32.5 +/- 1.7 nM with a slope of 1.07 +/- 0.02, respectively. Z-335 inhibited thromboxane A2 receptor-mediated human and guinea pig platelet aggregation in vitro and oral administration of this drug to guinea pigs inhibited U-46619- and collagen-induced platelet aggregation for 24 h. Z-335 dose-dependently prevented the occurrence of U-46619-induced pulmonary thromboembolism in mice and the protective effect of this drug (0.3 and 3 mg/kg, p.o.) lasted for 24 h. These results strongly suggest that Z-335 is a potent, orally active and long-lasting thromboxane A2 receptor antagonist, which may be useful as an antiplatelet drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/15-Hydroxy-11 alpha,9...,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Indans,
http://linkedlifedata.com/resource/pubmed/chemical/Phenylacetates,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Z 335,
http://linkedlifedata.com/resource/pubmed/chemical/cilostazol,
http://linkedlifedata.com/resource/pubmed/chemical/daltroban,
http://linkedlifedata.com/resource/pubmed/chemical/vapiprost
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0014-2999
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
357
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
53-60
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9788773-15-Hydroxy-11 alpha,9...,
pubmed-meshheading:9788773-Animals,
pubmed-meshheading:9788773-Biphenyl Compounds,
pubmed-meshheading:9788773-Drug Interactions,
pubmed-meshheading:9788773-Fibrinolytic Agents,
pubmed-meshheading:9788773-Guinea Pigs,
pubmed-meshheading:9788773-Heptanoic Acids,
pubmed-meshheading:9788773-Humans,
pubmed-meshheading:9788773-Indans,
pubmed-meshheading:9788773-Male,
pubmed-meshheading:9788773-Mice,
pubmed-meshheading:9788773-Mice, Inbred ICR,
pubmed-meshheading:9788773-Phenylacetates,
pubmed-meshheading:9788773-Platelet Aggregation,
pubmed-meshheading:9788773-Platelet Aggregation Inhibitors,
pubmed-meshheading:9788773-Pulmonary Embolism,
pubmed-meshheading:9788773-Receptors, Thromboxane,
pubmed-meshheading:9788773-Sulfonamides,
pubmed-meshheading:9788773-Tetrazoles,
pubmed-meshheading:9788773-Vasoconstrictor Agents
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
|
|
pubmed:affiliation |
Central Research Laboratories, Zeria Pharmaceutical, Saitama, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
